<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29050534</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Low copy numbers of complement C4 and homozygous deficiency of C4A may predispose to severe disease and earlier disease onset in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>600</StartPage><EndPage>609</EndPage><MedlinePgn>600-609</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0961203317735187</ELocationID><Abstract><AbstractText>Objectives Low copy numbers and deletion of complement C4 genes are potent risk factors for systemic lupus erythematosus (SLE). However, it is not known whether this genetic association affects the clinical outcome. We investigated C4 copy number variation and its relationship to clinical and serological features in a Northern European lupus cohort. Methods We genotyped the C4 gene locus using polymerase chain reaction (PCR)-based TaqMan assays in 169 patients with SLE classified according to the 1997 revised American College of Rheumatology (ACR) criteria and in 520 matched controls. In the patient group the mean C4 serum protein concentrations nephelometrically measured during a 12-month period prior to genetic analysis were compared to C4 gene copy numbers. Severity of disease was classified according to the intensity of the immunosuppressive regimens applied and compared to C4 gene copy numbers, too. In addition, we performed a TaqMan based analysis of three lupus-associated single-nucleotide polymorphisms (SNPs) located inside the major histocompatibility complex (MHC) to investigate the independence of complement C4 in association with SLE. Results Homozygous deficiency of the C4A isotype was identified as the strongest risk factor for SLE (odds ratio (OR)&#x2009;=&#x2009;5.329; p&#x2009;=&#x2009;7.7&#x2009;&#xd7;&#x2009;10<sup>-3</sup>) in the case-control comparison. Moreover, two copies of total C4 were associated with SLE (OR&#x2009;=&#x2009;3.699; p&#x2009;=&#x2009;6.8&#x2009;&#xd7;&#x2009;10<sup>-3</sup>). C4 serum levels were strongly related to C4 gene copy numbers in patients, the mean concentration ranging from 0.110&#x2009;g/l (two copies) to 0.256&#x2009;g/l (five to six copies; p&#x2009;=&#x2009;4.9&#x2009;&#xd7;&#x2009;10<sup>-6</sup>). Two copies of total C4 and homozygous deletion of C4A were associated with a disease course requiring cyclophosphamide therapy (OR&#x2009;=&#x2009;4.044; p&#x2009;=&#x2009;0.040 and OR&#x2009;=&#x2009;5.798; p&#x2009;=&#x2009;0.034, respectively). Homozygous deletion of C4A was associated with earlier onset of SLE (median 24 vs. 34 years; p&#x2009;=&#x2009;0.019) but not significant after correction for multiple testing. SNP analysis revealed a significant association of HLA-DRB1*0301 with SLE (OR&#x2009;=&#x2009;2.231; p&#x2009;=&#x2009;1.33&#x2009;&#xd7;&#x2009;10<sup>-5</sup>). Conclusions Our findings confirm the important role of complement C4 genes in the development of SLE. Beyond the impact on the susceptibility for lupus, C4 copy numbers may be related to earlier onset and a more severe course of the disease. The association of homozygous deletion of C4A and SLE is accompanied by the presence of HLA-DRB1*0301 without a proven pathophysiological mechanism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>J&#xfc;ptner</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1 First Clinic of Internal Medicine, University Hospital of Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flachsbart</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>2 Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caliebe</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>3 Institute of Medical Informatics and Statistics, Christian-Albrechts-University of Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieb</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>4 Institute of Epidemiology, Christian-Albrechts-University of Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 First Clinic of Internal Medicine, University Hospital of Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeuner</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1 First Clinic of Internal Medicine, University Hospital of Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franke</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>2 Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>J O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>1 First Clinic of Internal Medicine, University Hospital of Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C553502">HLA-DRB1*03:01 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-49-4</RegistryNumber><NameOfSubstance UI="D015934">Complement C4a</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015934" MajorTopicYN="N">Complement C4a</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056915" MajorTopicYN="Y">DNA Copy Number Variations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="Y">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018628" MajorTopicYN="Y">Gene Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="Y">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLA</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">complement C4</Keyword><Keyword MajorTopicYN="N">copy number variation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29050534</ArticleId><ArticleId IdType="pmc">PMC5871021</ArticleId><ArticleId IdType="doi">10.1177/0961203317735187</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 2010; 6: 683&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135416</ArticleId><ArticleId IdType="pubmed">21060334</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Chung EK, Zhou B, et al. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun 2004; 7: 98&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">14719377</ArticleId></ArticleIdList></Reference><Reference><Citation>Boteva L, Morris DL, Cort&#xe9;s-Hern&#xe1;ndez J, Martin J, Vyse TJ, Fernando MM. Genetically determined partial complement C4 deficiency states are not independent risk factors for SLE in UK and Spanish populations. Am J Hum Genet 2012; 90: 445&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3309188</ArticleId><ArticleId IdType="pubmed">22387014</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Chung EK, Wu YL, et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): Low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 2007; 80: 1037&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867093</ArticleId><ArticleId IdType="pubmed">17503323</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Krawczak M, Nikolaus S, von Eberstein H, Croucher PJ, El Mokhtari NE, Schreiber S. PopGen: Population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. Community Genet 2006; 9: 55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490960</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YL, Savelli SL, Yang Y, et al. Sensitive and specific real-time polymerase chain reaction assays to accurately determine copy number variations (CNVs) of human complement C4A, C4B, C4-long, C4-short, and RCCX modules: Elucidation of C4 CNVs in 50 consanguineous subjects with defined HLA genotypes. J Immunol 2007; 179: 3012&#x2013;3025.</Citation><ArticleIdList><ArticleId IdType="pubmed">17709516</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Vega FM, Lazaruk KD, Rhodes MD, Wenz MH. Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. Mutat Res 2005; 573: 111&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829242</ArticleId></ArticleIdList></Reference><Reference><Citation>Flachsbart F, Caliebe A, Heinsen FA, et al. Investigation of complement component C4 copy number variation in human longevity. PLoS One 2014; 9: e86188&#x2013;e86188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899116</ArticleId><ArticleId IdType="pubmed">24465950</ArticleId></ArticleIdList></Reference><Reference><Citation>Man XY, Luo HR, Li XP, Yao YG, Mao CZ, Zhang YP. Polymerase chain reaction based C4AQ0 and C4BQ0 genotyping: Association with systemic lupus erythematosus in southwest Han Chinese. Ann Rheum Dis 2003; 62: 71&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1754297</ArticleId><ArticleId IdType="pubmed">12480675</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena K, Kitzmiller KJ, Wu YL, et al. Great genotypic and phenotypic diversities associated with copy-number variations of complement C4 and RP-C4-CYP21-TNX (RCCX) modules: A comparison of Asian-Indian and European American populations. Mol Immunol 2009; 46: 1289&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2716727</ArticleId><ArticleId IdType="pubmed">19135723</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Chung EK, Zhou B, et al. Diversity in intrinsic strengths of the human complement system: Serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index. J Immunol 2003; 171: 2734&#x2013;2745.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond A, Ollier W, Walport MJ. Effects of C4 null alleles and homoduplications on quantitative expression of C4A and C4B. Clin Exp Immunol 1992; 88: 163&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1554358</ArticleId><ArticleId IdType="pubmed">1563101</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragon-Durey MA, Rougier N, Clauvel JP, et al. Lack of evidence of a specific role for C4A gene deficiency in determining disease susceptibility among C4-deficient patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2001; 123: 133&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1905972</ArticleId><ArticleId IdType="pubmed">11168010</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering MC, Walport MJ. Links between complement abnormalities and systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39: 133&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">10725062</ArticleId></ArticleIdList></Reference><Reference><Citation>Giles BM, Boackle SA. Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. Immunol Res 2013; 55: 10&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4018221</ArticleId><ArticleId IdType="pubmed">22941560</ArticleId></ArticleIdList></Reference><Reference><Citation>Schifferli JA, Ng YC, Peters DK. The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 1986; 315: 488&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">2942776</ArticleId></ArticleIdList></Reference><Reference><Citation>Gullstrand B, M&#xe5;rtensson U, Sturfelt G, Bengtsson AA, Truedsson L. Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol 2009; 156: 303&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759479</ArticleId><ArticleId IdType="pubmed">19302245</ArticleId></ArticleIdList></Reference><Reference><Citation>Traustadottir KH, Sigfusson A, Steinsson K, Erlendsson K. C4A deficiency and elevated level of immune complexes: The mechanism behind increased susceptibility to systemic lupus erythematosus. J Rheumatol 2002; 29: 2359&#x2013;2366.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415592</ArticleId></ArticleIdList></Reference><Reference><Citation>Law SK, Dodds AW, Porter RR. A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. EMBO J 1984; 3: 1819&#x2013;1823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC557602</ArticleId><ArticleId IdType="pubmed">6332733</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatenby PA, Barbosa JE, Lachmann PJ. Differences between C4A and C4B in the handling of immune complexes: The enhancement of CR1 binding is more important than the inhibition of immunoprecipitation. Clin Exp Immunol 1990; 79: 158&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1534744</ArticleId><ArticleId IdType="pubmed">2138067</ArticleId></ArticleIdList></Reference><Reference><Citation>Arason GJ, Steinsson K, Kolka R, V&#xed;kingsd&#xf3;ttir T, D&#x2019;Ambrogio MS, Valdimarsson H. Patients with systemic lupus erythematosus are deficient in complement-dependent prevention of immune precipitation. Rheumatology (Oxford) 2004; 43: 783&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pubmed">15054157</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng YC, Peters DK, Walport MJ. Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. Arthritis Rheum 1988; 31: 99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">3345233</ArticleId></ArticleIdList></Reference><Reference><Citation>Prodeus AP, Goerg S, Shen LM, et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998; 9: 721&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">9846493</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, Agyemang AF, Alimzhanov MB, et al. Complement C4 maintains peripheral B-cell tolerance in a myeloid cell dependent manner. Eur J Immunol 2013; 43: 2441&#x2013;2450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086186</ArticleId><ArticleId IdType="pubmed">23749435</ArticleId></ArticleIdList></Reference><Reference><Citation>Skarsv&#xe5;g S. The importance of C4A null genes in Norwegian patients with systemic lupus erythematosus. Scand J Immunol 1995; 42: 572&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">7481564</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinsson K, J&#xf3;nsd&#xf3;ttir S, Arason GJ, et al. A study of the association of HLA DR, DQ, and complement C4 alleles with systemic lupus erythematosus in Iceland. Ann Rheum Dis 1998; 57: 503&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1752717</ArticleId><ArticleId IdType="pubmed">9797559</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeazzi M, Sebastiani GD, Morozzi G, et al. HLA class II DNA typing in a large series of European patients with systemic lupus erythematosus: Correlations with clinical and autoantibody subsets. Medicine (Baltimore) 2002; 81: 169&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">11997714</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando MM, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: A review and pooled analysis. PLoS Genet 2008; 4: e1000024&#x2013;e1000024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291482</ArticleId><ArticleId IdType="pubmed">18437207</ArticleId></ArticleIdList></Reference><Reference><Citation>Reveille JD, Moulds JM, Ahn C, et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998; 41: 1161&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">9663471</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan YJ, Luo XB, Shen N. Current advances in lupus genetic and genomic studies in Asia. Lupus 2010; 19: 1374&#x2013;1383.</Citation><ArticleIdList><ArticleId IdType="pubmed">20947545</ArticleId></ArticleIdList></Reference><Reference><Citation>Price P, Witt C, Allcock R, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999; 167: 257&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YL, Hauptmann G, Viguier M, Yu CY. Molecular basis of complete complement C4 deficiency in two North-African families with systemic lupus erythematosus. Genes Immun 2009; 10: 433&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2767122</ArticleId><ArticleId IdType="pubmed">19279649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim I, Kim YJ, Kim K, et al. Genetic studies of systemic lupus erythematosus in Asia: Where are we now? Genes Immun 2009; 10: 421&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">19357696</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunckley H, Gatenby PA, Hawkins B, Naito S, Serjeantson SW. Deficiency of C4A is a genetic determinant of systemic lupus erythematosus in three ethnic groups. J Immunogenet 1987; 14: 209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">3502648</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollid LM. Coeliac disease: Dissecting a complex inflammatory disorder. Nat Rev Immunol 2002; 2: 647&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">12209133</ArticleId></ArticleIdList></Reference><Reference><Citation>James EA, Moustakas AK, Bui J, et al. HLA-DR1001 presents &#x201c;altered-self&#x201d; peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis Rheum 2010; 62: 2909&#x2013;2918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952065</ArticleId><ArticleId IdType="pubmed">20533291</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong DL, Zidovetzki R, Alarc&#xf3;n-Riquelme ME, et al. GWAS identifies novel SLE susceptibility genes and explains the association of the HLA region. Genes Immun 2014; 15: 347&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4156543</ArticleId><ArticleId IdType="pubmed">24871463</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110&#x2013;2121.</Citation><ArticleIdList><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Boumpas DT, Austin HA, 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">1356175</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampeli E, Klinman DM, Gershwin ME, Moutsopoulos HM. A comprehensive evaluation for the treatment of lupus nephritis. J Autoimmun 2017; 78: 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">28082046</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>